Newsroom

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

CSL Limited Signs Commercial License Agreement with Selexis SA

Jul 26, 2011 1:46:21 PM

CSL Limited Signs Commercial License Agreement with Selexis SCSL Limited will use Selexis Technologies for Development of Therapeutic Antibody

Geneva, Switzerland (PRNEWSWIRE) July 26, 2011 – Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited (ASX:CSL Australia) has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012. This commercial license agreement provides CSL with the rights to use a cell line, generated using the Selexis SUREtechnology Platform, for the cGMP production of an undisclosed antibody.

“We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform,” said Dr. Igor Fisch, CEO, Selexis SA. “This agreement represents Selexis’ commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL.”

Terms of the agreement were not disclosed.

About CSL Limited
Headquartered in Melbourne, Australia, with major facilities in Germany, Switzerland, and the U.S., CSL has more than 10,000 employees working in 27 countries. The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years of experience in the development and manufacture of vaccines and plasma protein biotherapies. In fiscal 2010, the company produced revenues of approximately A$4.5 billion.
For more information visit http://www.csl.com.au

Featured